Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 28 DAY versus NORLESTRIN FE 2 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 28 DAY versus NORLESTRIN FE 2 5 50.
BREVICON 28-DAY vs NORLESTRIN FE 2.5/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) via negative feedback on the hypothalamus and pituitary. Increases cervical mucus viscosity to impede sperm penetration and induces endometrial atrophy to prevent implantation.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
One tablet orally once daily, each containing 2.5 mg norethindrone acetate and 50 mcg ethinyl estradiol, plus 7 iron tablets (75 mg ferrous fumarate) taken during the placebo week.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Norethindrone: ~8-10 hours (terminal), requiring daily dosing for stable contraceptive effect. Ethinyl estradiol: ~13-21 hours (terminal), supporting once-daily administration.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, with enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive